Treatment with medications affecting dopaminergic and serotonergic mechanisms: Effects on fluency and anxiety in persons who stutter

Stager, Sheila V.; Calis, Karim A.; Grothe, Dale R.; Bloch, Meir; Berensen, Nannette M.; Smith, Paul J.; Braun, Allen R.

doi:10.1016/j.jfludis.2005.09.004

Cited by 41 publications

(20 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The discovery that stuttering severity is less determined by heritability than the disorder itself [24,38] has already established a more optimistic outlook for therapeutic success. Genetic findings are also likely to facilitate attempts of developing pharmaceutical treatment approaches of stuttering currently under way [74,75] . In this respect, Alzheimer's disease provides an encouraging prospect for the potential clinical implications.…”

Section: Clinical Considerationsmentioning

confidence: 99%

Genetic Bases of Stuttering: The State of the Art, 2011

Kraft

Yairi

2011

Folia Phoniatr Logop

102

View full text Add to dashboard Cite

Objective: The literature on the genetics of stuttering is reviewed with special reference to the historical development from psychosocial explanations leading up to current biological research of gene identification. Summary: A gradual progression has been made from the early crude methods of counting percentages of stuttering probands who have relatives who stutter to recent studies using entire genomes of DNA collected from each participant. Despite the shortcomings of some early studies, investigators have accumulated a substantial body of data showing a large presence of familial stuttering. This encouraged more refined research in the form of twin studies. Concordance rates among twins were sufficiently high to lend additional support to the genetic perspective of stuttering. More sophisticated aggregation studies and segregation analyses followed, producing data that matched recognized genetic models, providing the final ‘go ahead’ to proceed from the behavior/statistical genetics into the sphere of biological genetics. Recent linkage and association studies have begun to reveal contributing genes to the disorder. Conclusion: No definitive findings have been made regarding which transmission model, chromosomes, genes, or sex factors are involved in the expression of stuttering in the population at large. Future research and clinical implications are discussed.

show abstract

Section: Clinical Considerationsmentioning

confidence: 99%

Genetic Bases of Stuttering: The State of the Art, 2011

Kraft

Yairi

2011

Folia Phoniatr Logop

102

View full text Add to dashboard Cite

show abstract

“…The BG’s striatum receives the densest dopamine innervation in the brain, and in repeated findings, drugs that block type D2 dopamine receptors (D2Rs) have been shown to be effective in reducing stuttering (Brady, 1991; Maguire et al, 2004; Stager et al, 2005; Tran, Maguire, Franklin, & Riley, 2008). Although other parts of the brain also have D2Rs, it is likely that a major part of the ameliorative action of the D2R blockers was in the BG.…”

Section: Introductionmentioning

confidence: 99%

Computational modeling of stuttering caused by impairments in a basal ganglia thalamo-cortical circuit involved in syllable selection and initiation

et al. 2013

View full text Add to dashboard Cite

A typical white-matter integrity and elevated dopamine levels have been reported for individuals who stutter. We investigated how such abnormalities may lead to speech dysfluencies due to their effects on a syllable-sequencing circuit that consists of basal ganglia (BG), thalamus, and left ventral premotor cortex (vPMC). “Neurally impaired” versions of the neurocomputational speech production model GODIVA were utilized to test two hypotheses: (1) that white-matter abnormalities disturb the circuit via corticostriatal projections carrying copies of executed motor commands, and (2) that dopaminergic abnormalities disturb the circuit via the striatum. Simulation results support both hypotheses: in both scenarios, the neural abnormalities delay readout of the next syllable’s motor program, leading to dysfluency. The results also account for brain imaging findings during dysfluent speech. It is concluded that each of the two abnormality types can cause stuttering moments, probably by affecting the same BG-thalamus-vPMC circuit.

show abstract

“…Verbal fluency improves following the administration of haloperidol and other dopamine antagonists, a neurotransmitter in the motor circuit [14]. Dopamine antagonists generally markedly increase bradykinesia and rigidity of the limbs in parkinsonian patients.…”

Section: Discussionmentioning

confidence: 99%

Aggravated stuttering following subthalamic deep brain stimulation in Parkinson's disease - two cases

Toft

Dietrichs

2011

BMC Neurol

View full text Add to dashboard Cite

Stuttering is a speech disorder with disruption of verbal fluency which is occasionally present in patients with Parkinson's disease (PD). Long-term medical management of PD is frequently complicated by fluctuating motor functions and dyskinesias. High-frequency deep brain stimulation (DBS) of the subthalamic nucleus (STN) is an effective treatment of motor fluctuations and is the most common surgical procedure in PD. Here we report the re-occurrence and aggravation of stuttering following STN-DBS in two male patients treated for advanced PD. In both patients the speech fluency improved considerably when the neurostimulator was turned off, indicating that stuttering aggravation was related to neurostimulation of the STN itself, its afferent or efferent projections and/or to structures localized in the immediate proximity. This report supports previous studies demonstrating that lesions of the basal ganglia-thalamocortical motor circuit, including the STN, is involved in the development of stuttering. In advanced PD STN-DBS is generally an effective and safe treatment. However, patients with PD and stuttering should be informed about the risk of aggravated symptoms following surgical therapy.

show abstract

Treatment with medications affecting dopaminergic and serotonergic mechanisms: Effects on fluency and anxiety in persons who stutter

Cited by 41 publications

References 51 publications

Genetic Bases of Stuttering: The State of the Art, 2011

Genetic Bases of Stuttering: The State of the Art, 2011

Computational modeling of stuttering caused by impairments in a basal ganglia thalamo-cortical circuit involved in syllable selection and initiation

Aggravated stuttering following subthalamic deep brain stimulation in Parkinson's disease - two cases

Contact Info

Product

Resources

About